KOD

Kodiak Sciences

KOD

Attention (50-day avg)0.01%

Attention rank (50-day avg)#549

Bullish sentiment (50-day avg)55%

Price to earnings ratio-20.8

Market capitalization5.7B

Earnings per share-4.19

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-230M

Social

What share of all stock conversation is about KOD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.07% -0.17	0.04% +0.04	0.01% +0.01	0% +0

Sep 29

The author expects Kodiak Sciences Inc. to have a private placement or underwritten public offering, with a price near $50 to provide a margin of safety, and believes this will be a win for the company's treasury.
The stock has been experiencing a short squeeze, with some users expecting a price of $100 or higher, and others predicting a drop below $70.
The author is holding a short position, but is also long on the stock, and believes it will drop below $70 before Friday.

Generated by AI

Sentiment

Of the messages about KOD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	42.96% -9.89	50.7% -49.3	54.37% -16.67	64.66% -26.01
Bearish	57.04% +9.89	49.3% +49.3	45.63% +16.67	35.34% +26.01

Bullish· Sep 29

The stock has shown an explosion in growth, with a 200% increase, making it a rare opportunity for traders to hold and profit.
The company's phase 3 results and product have been successful, and the stock is expected to continue its upward trend, with some analysts predicting a price of $100 or more.
The stock's strong fight against bears and potential catalysts, such as a private placement, and upcoming phase 3 readout, are expected to drive the price higher, with some analysts predicting a price of $50 or more.

Bearish· Sep 29

Kodiak Sciences Inc. (KOD) is experiencing a severe cash burn, which may lead to a dilutive offering, potentially making the stock more diluted than expected.
The company's inability to secure funding immediately may result in momentum fading, making the dilutive offering more impactful, and increasing the risk for investors.
The stock's price may be artificially inflated by market makers, and a correction is expected, with some predicting a drop to $50 or below, making it a good time to go short.

Generated by AI

Topics

Of the messages about KOD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	8.89%	21.48%	73.04%	18.88%
Technical Analysis	24.44%	48.99%	16.82%	3.51%
Analysts	35.56%	18.79%	6.45%	2.4%
Macro	31.11%	9.4%	3.23%	75.05%
Controversies	0%	1.34%	0.46%	0.06%
Earnings	0%	0%	0%	0.1%

Analysts· Feb 24

Kodiak Sciences' price target was lowered by several analysts, with the lowest target at $12 by Citigroup and the highest at $35 by Truist Financial.
Morgan Stanley cut its price target for Kodiak Sciences to $17, while JP Morgan downgraded the stock to neutral from overweight and cut its target to $21.
Analysts' consensus on buying Kodiak Sciences is at 74%, indicating mild confidence in the stock.

Announcements· Jul 24

Kodiak Sciences Inc. ($KOD) has discontinued development of its lead eye disorder therapeutic, Tarcocimab, after it failed two out of three Phase 3 trials.
The company's shares plummeted 47% in premarket trading after the announcement, extending their fall.
Kodiak Sciences has announced topline results from its Phase 3 studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema, and has provided an update on its development program.

Technical Analysis· Sep 29

The stock's price has been consolidating in a range of $31–$35 for weeks, and the recent gap up to $95.77 on Sep 28 was due to positive Phase 3 DAYBREAK wAMD trial data, causing a binary valuation repricing.
A close above $89.69 would confirm the breakout and extend the stock's price toward the $96–$120 analyst-target zone, while a pullback that holds above $61.28 would be read as healthy digestion of the move.
The stock's trend is shifting due to clear signs of ATM dilution, including the Invisible Wall, Heavy Distribution, VWAP Resistance, and Volume Spike on Dips, which may indicate institutional dumping and a rapid gap fill down to the $50-$60 zone.

Generated by AI

Community

Of the messages about KOD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	10.79%	15.51%	28.81%	33.32%
Newcomers	89.21%	84.49%	71.19%	66.68%

Regulars· Sep 29

The regulars are focused on the potential for Kodiak Sciences Inc. ($KOD) to find support around $85-90, with some investors expecting a price increase once the initial profit-taking settles down and the company's catalysts are met.
There is speculation among the regulars that Kodiak Sciences Inc. ($KOD) may announce another private placement, which could lead to dilution and a potential price increase, possibly this week or early next.
The regulars are also discussing the company's strategy, with some questioning whether they are trying to "bore us to death" with a lack of news and catalysts, and others pointing out that all good news has already been priced in at the current market cap.

Newcomers· Sep 29

Many new investors are buying into Kodiak Sciences Inc. (KOD) after a significant price increase, with some even shorting the stock in hopes of a crash.
There are concerns about a potential public offering, with some speculating that the company will price it at a premium, potentially around $50 per share, to secure funding for future expenses.
Some users are predicting a sharp decline in the stock price, with one user even stating that the company will likely drop below $70 by the end of the week, while another user is confident that the stock will reach $100 or higher.

Generated by AI

News

Exclusive BAC Article: Kodiak Sciences; Zenkuda Wet-AMD Win, Multi-Indication BLA Filings Q4 2026, KSI-501 Expansion Into DME, And Catalysts (NASDAQ:KOD)

16h agoSeeking Alpha

KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears

Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.

21h agoYahoo Finance

H.C. Wainwright raises Kodiak Sciences stock price target on trial data

23h agoInvesting.com

Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?

1d agoYahoo Finance

Why Kodiak Sciences Skyrocketed Today

The biotech is developing innovative therapies for people with eye diseases.

1d agoYahoo Finance

KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’

Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.

1d agoYahoo Finance

Also Discussed

Investors talking about KOD also mention

#	Name	Attention
1	IGMS - IGM Biosciences, Inc.	——
2	Relmada Therapeutics Inc.RLMD	0%0
3	IDEAYA Biosciences Inc.IDYA	0%-0.01
4	Bicycle Therapeutics plc - ADRBCYC	0%0
5	MRTX - Mirati Therapeutics, Inc.	——
6	BridgeBio Pharma Inc.BBIO	0%-0.02
7	Regenxbio Inc.RGNX	0%+0
8	KRTX - Karuna Therapeutics, Inc.	——
9	Replimune Group, Inc.REPL	0%0
10	Prelude Therapeutics IncorporatedPRLD	0%0

Kodiak Sciences Inc.

Healthcare
Biotechnology

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases. The company works on treatments for conditions that affect the retina and can lead to vision loss, with a portfolio centered on ophthalmology and retinal vascular disorders. Its current programs include late-stage and earlier-stage candidates built around its proprietary Antibody Biopolymer Conjugate platform, which is designed to support the development of next-generation eye medicines. Kodiak Sciences Inc. serves the biopharmaceutical and ophthalmic research markets by advancing specialized therapeutics for diseases such as wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy. Headquartered in Palo Alto, California, and founded in 2009, the company remains focused on researching, developing, and commercializing retina-directed medicines for patients and eye-care specialists.

Website

Location

1200 Page Mill Road

Palo Alto, CA, 94304

United States

Social

What share of all stock conversation is about KOD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.07% -0.17	0.04% +0.04	0.01% +0.01	0% +0

Sep 29

The author expects Kodiak Sciences Inc. to have a private placement or underwritten public offering, with a price near $50 to provide a margin of safety, and believes this will be a win for the company's treasury.
The stock has been experiencing a short squeeze, with some users expecting a price of $100 or higher, and others predicting a drop below $70.
The author is holding a short position, but is also long on the stock, and believes it will drop below $70 before Friday.

Generated by AI

Sentiment

Of the messages about KOD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	42.96% -9.89	50.7% -49.3	54.37% -16.67	64.66% -26.01
Bearish	57.04% +9.89	49.3% +49.3	45.63% +16.67	35.34% +26.01

Bullish· Sep 29

The stock has shown an explosion in growth, with a 200% increase, making it a rare opportunity for traders to hold and profit.
The company's phase 3 results and product have been successful, and the stock is expected to continue its upward trend, with some analysts predicting a price of $100 or more.
The stock's strong fight against bears and potential catalysts, such as a private placement, and upcoming phase 3 readout, are expected to drive the price higher, with some analysts predicting a price of $50 or more.

Bearish· Sep 29

Kodiak Sciences Inc. (KOD) is experiencing a severe cash burn, which may lead to a dilutive offering, potentially making the stock more diluted than expected.
The company's inability to secure funding immediately may result in momentum fading, making the dilutive offering more impactful, and increasing the risk for investors.
The stock's price may be artificially inflated by market makers, and a correction is expected, with some predicting a drop to $50 or below, making it a good time to go short.

Generated by AI

Topics

Of the messages about KOD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	8.89%	21.48%	73.04%	18.88%
Technical Analysis	24.44%	48.99%	16.82%	3.51%
Analysts	35.56%	18.79%	6.45%	2.4%
Macro	31.11%	9.4%	3.23%	75.05%
Controversies	0%	1.34%	0.46%	0.06%
Earnings	0%	0%	0%	0.1%

Analysts· Feb 24

Kodiak Sciences' price target was lowered by several analysts, with the lowest target at $12 by Citigroup and the highest at $35 by Truist Financial.
Morgan Stanley cut its price target for Kodiak Sciences to $17, while JP Morgan downgraded the stock to neutral from overweight and cut its target to $21.
Analysts' consensus on buying Kodiak Sciences is at 74%, indicating mild confidence in the stock.

Announcements· Jul 24

Kodiak Sciences Inc. ($KOD) has discontinued development of its lead eye disorder therapeutic, Tarcocimab, after it failed two out of three Phase 3 trials.
The company's shares plummeted 47% in premarket trading after the announcement, extending their fall.
Kodiak Sciences has announced topline results from its Phase 3 studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema, and has provided an update on its development program.

Technical Analysis· Sep 29

The stock's price has been consolidating in a range of $31–$35 for weeks, and the recent gap up to $95.77 on Sep 28 was due to positive Phase 3 DAYBREAK wAMD trial data, causing a binary valuation repricing.
A close above $89.69 would confirm the breakout and extend the stock's price toward the $96–$120 analyst-target zone, while a pullback that holds above $61.28 would be read as healthy digestion of the move.
The stock's trend is shifting due to clear signs of ATM dilution, including the Invisible Wall, Heavy Distribution, VWAP Resistance, and Volume Spike on Dips, which may indicate institutional dumping and a rapid gap fill down to the $50-$60 zone.

Generated by AI

Community

Of the messages about KOD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	10.79%	15.51%	28.81%	33.32%
Newcomers	89.21%	84.49%	71.19%	66.68%

Regulars· Sep 29

The regulars are focused on the potential for Kodiak Sciences Inc. ($KOD) to find support around $85-90, with some investors expecting a price increase once the initial profit-taking settles down and the company's catalysts are met.
There is speculation among the regulars that Kodiak Sciences Inc. ($KOD) may announce another private placement, which could lead to dilution and a potential price increase, possibly this week or early next.
The regulars are also discussing the company's strategy, with some questioning whether they are trying to "bore us to death" with a lack of news and catalysts, and others pointing out that all good news has already been priced in at the current market cap.

Newcomers· Sep 29

Many new investors are buying into Kodiak Sciences Inc. (KOD) after a significant price increase, with some even shorting the stock in hopes of a crash.
There are concerns about a potential public offering, with some speculating that the company will price it at a premium, potentially around $50 per share, to secure funding for future expenses.
Some users are predicting a sharp decline in the stock price, with one user even stating that the company will likely drop below $70 by the end of the week, while another user is confident that the stock will reach $100 or higher.

Generated by AI

Kodiak Sciences

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Analysts· Feb 24

Announcements· Jul 24

Technical Analysis· Sep 29

Regulars· Sep 29

Newcomers· Sep 29

Exclusive BAC Article: Kodiak Sciences; Zenkuda Wet-AMD Win, Multi-Indication BLA Filings Q4 2026, KSI-501 Expansion Into DME, And Catalysts (NASDAQ:KOD)

KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears

H.C. Wainwright raises Kodiak Sciences stock price target on trial data

Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?

Why Kodiak Sciences Skyrocketed Today

KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’

Also Discussed

Kodiak Sciences Inc.

Company Information

Location

Exclusive BAC Article: Kodiak Sciences; Zenkuda Wet-AMD Win, Multi-Indication BLA Filings Q4 2026, KSI-501 Expansion Into DME, And Catalysts (NASDAQ:KOD)

KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears

H.C. Wainwright raises Kodiak Sciences stock price target on trial data

Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?

Why Kodiak Sciences Skyrocketed Today

KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Analysts· Feb 24

Announcements· Jul 24

Technical Analysis· Sep 29

Regulars· Sep 29

Newcomers· Sep 29